Biosimilars Immunology Roundup for May 2023—Podcast Edition

On this episode, we’re going to be recapping some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.

Show notes

FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar

Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar

Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J

Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology

Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings

Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption

Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders

Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants

RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator